Management of OAB in Female Patients .

• Status: Completed
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (OAB) in a double-blinded prospective randomized placebo-controlled trial.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Elsayed Abdelhalim Elsayed
• Treatments: Mirabegron; Tadalafil

Criteria

Inclusion Criteria:

• Women from 18 to 65 years of age with LUTs due to OAB

Exclusion Criteria:

• Severe cardiovascular disorders. \

• Severe neurogenic dysfunction.

• Drug administration which interfere with bladder function .

• Abnormal bleeding profile.

• A verified urinary tract infection as determined by urinalysis and/or urine culture during screening